Jay Parrish's most recent trade in Vir Biotechnology Inc was a trade of 6,944 Common Stock done at an average price of $51.4 . Disclosure was reported to the exchange on April 1, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 51.40 per share. | 01 Apr 2021 | 6,944 | 9,260 (0%) | 0% | 51.4 | 356,956 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 4,629 | 4,630 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 01 Apr 2021 | 4,629 | 13,889 (0%) | 0% | 1.5 | 6,874 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 2,315 | 37,037 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 01 Apr 2021 | 2,315 | 16,204 (0%) | 0% | 1.6 | 3,646 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 63.44 per share. | 01 Mar 2021 | 6,944 | 9,260 (0%) | 0% | 63.4 | 440,531 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 4,630 | 9,259 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.49 per share. | 01 Mar 2021 | 4,630 | 13,890 (0%) | 0% | 1.5 | 6,876 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.58 per share. | 01 Mar 2021 | 2,314 | 16,204 (0%) | 0% | 1.6 | 3,645 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 2,314 | 39,352 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 69.91 per share. | 01 Feb 2021 | 6,944 | 222,222 (0%) | 0% | 69.9 | 485,424 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 01 Feb 2021 | 4,630 | 229,166 (0%) | 0% | 1.6 | 7,292 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 4,630 | 41,666 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 2,314 | 13,889 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 01 Feb 2021 | 2,314 | 224,536 (0%) | 0% | 1.5 | 3,436 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 26.32 per share. | 04 Jan 2021 | 6,945 | 222,222 (0%) | 0% | 26.3 | 182,795 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 6,945 | 16,203 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 04 Jan 2021 | 6,945 | 229,167 (0%) | 0% | 1.5 | 10,313 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.53 per share. | 01 Dec 2020 | 6,945 | 222,222 (0%) | 0% | 31.5 | 218,968 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 4,630 | 23,148 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.49 per share. | 01 Dec 2020 | 4,630 | 226,852 (0%) | 0% | 1.5 | 6,876 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 01 Dec 2020 | 2,315 | 229,167 (0%) | 0% | 1.6 | 3,646 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 2,315 | 46,296 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.27 per share. | 02 Nov 2020 | 6,944 | 222,222 (0%) | 0% | 31.3 | 217,153 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 4,629 | 27,778 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.48 per share. | 02 Nov 2020 | 4,629 | 226,851 (0%) | 0% | 1.5 | 6,874 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 2,315 | 48,611 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 02 Nov 2020 | 2,315 | 229,166 (0%) | 0% | 1.6 | 3,646 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 34.75 per share. | 01 Oct 2020 | 6,945 | 222,222 (0%) | 0% | 34.8 | 241,342 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 4,630 | 32,407 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.49 per share. | 01 Oct 2020 | 4,630 | 226,852 (0%) | 0% | 1.5 | 6,876 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 01 Oct 2020 | 2,315 | 229,167 (0%) | 0% | 1.6 | 3,646 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2020 | 2,315 | 50,926 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 01 Sep 2020 | 6,943 | 229,165 (0%) | 0% | 1.6 | 10,935 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 39.15 per share. | 01 Sep 2020 | 6,943 | 222,222 (0%) | 0% | 39.1 | 271,796 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Sep 2020 | 6,943 | 53,241 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 47.65 per share. | 03 Aug 2020 | 11,110 | 222,222 (0%) | 0% | 47.7 | 529,404 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.49 per share. | 03 Aug 2020 | 9,259 | 231,481 (0%) | 0% | 1.5 | 13,750 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 9,259 | 37,037 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.57 per share. | 03 Aug 2020 | 1,851 | 233,332 (0%) | 0% | 1.6 | 2,915 | Common Stock |
| Vir Biotechnology Inc | Jay Parrish | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 1,851 | 60,184 | - | - | Stock Option (Right to Buy) |